Cargando…

Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhale...

Descripción completa

Detalles Bibliográficos
Autores principales: Llanos-Paez, Carolina, Ambery, Claire, Yang, Shuying, Beerahee, Misba, Plan, Elodie L., Karlsson, Mats O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314306/
https://www.ncbi.nlm.nih.gov/pubmed/35233731
http://dx.doi.org/10.1007/s11095-022-03194-1
_version_ 1784754290019008512
author Llanos-Paez, Carolina
Ambery, Claire
Yang, Shuying
Beerahee, Misba
Plan, Elodie L.
Karlsson, Mats O.
author_facet Llanos-Paez, Carolina
Ambery, Claire
Yang, Shuying
Beerahee, Misba
Plan, Elodie L.
Karlsson, Mats O.
author_sort Llanos-Paez, Carolina
collection PubMed
description PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhaled triple therapy with twice daily inhaled dual therapy in patients with chronic obstructive pulmonary disease (COPD). Patient reported outcome data, obtained by using The Evaluating Respiratory Symptoms in COPD (E-RS:COPD) questionnaire, from the FULFIL study were analyzed using an NLME item-based response theory model (IRT). The change from baseline (CFB) in E-RS:COPD total score over 4-week intervals for each treatment arm was obtained using the IRT and compared with published results obtained with a mixed model repeated measures (MMRM) analysis. RESULTS: The IRT included a graded response model characterizing item parameters and a Weibull function combined with an offset function to describe the COPD symptoms-time course in patients receiving either triple therapy (n = 907) or dual therapy (n = 894). The IRT improved precision of the estimated drug effect compared to MMRM, resulting in a sample size of at least 3.64 times larger for the MMRM analysis to achieve the IRT precision in the CFB estimate. CONCLUSION: This study shows the advantage of IRT over MMRM with a direct comparison of the same primary endpoint for the two analyses using the same observed clinical trial data, resulting in an increased confidence in Phase III. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03194-1.
format Online
Article
Text
id pubmed-9314306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93143062022-07-27 Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Llanos-Paez, Carolina Ambery, Claire Yang, Shuying Beerahee, Misba Plan, Elodie L. Karlsson, Mats O. Pharm Res Original Research Article PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhaled triple therapy with twice daily inhaled dual therapy in patients with chronic obstructive pulmonary disease (COPD). Patient reported outcome data, obtained by using The Evaluating Respiratory Symptoms in COPD (E-RS:COPD) questionnaire, from the FULFIL study were analyzed using an NLME item-based response theory model (IRT). The change from baseline (CFB) in E-RS:COPD total score over 4-week intervals for each treatment arm was obtained using the IRT and compared with published results obtained with a mixed model repeated measures (MMRM) analysis. RESULTS: The IRT included a graded response model characterizing item parameters and a Weibull function combined with an offset function to describe the COPD symptoms-time course in patients receiving either triple therapy (n = 907) or dual therapy (n = 894). The IRT improved precision of the estimated drug effect compared to MMRM, resulting in a sample size of at least 3.64 times larger for the MMRM analysis to achieve the IRT precision in the CFB estimate. CONCLUSION: This study shows the advantage of IRT over MMRM with a direct comparison of the same primary endpoint for the two analyses using the same observed clinical trial data, resulting in an increased confidence in Phase III. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03194-1. Springer US 2022-03-01 2022 /pmc/articles/PMC9314306/ /pubmed/35233731 http://dx.doi.org/10.1007/s11095-022-03194-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research Article
Llanos-Paez, Carolina
Ambery, Claire
Yang, Shuying
Beerahee, Misba
Plan, Elodie L.
Karlsson, Mats O.
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title_full Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title_fullStr Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title_full_unstemmed Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title_short Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
title_sort improved confidence in a confirmatory stage by application of item-based pharmacometrics model: illustration with a phase iii active comparator-controlled trial in copd patients
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314306/
https://www.ncbi.nlm.nih.gov/pubmed/35233731
http://dx.doi.org/10.1007/s11095-022-03194-1
work_keys_str_mv AT llanospaezcarolina improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients
AT amberyclaire improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients
AT yangshuying improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients
AT beeraheemisba improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients
AT planelodiel improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients
AT karlssonmatso improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients